Danske Bank A S Sells 83,562 Shares of DexCom, Inc. $DXCM

Key Points

• Danske Bank A/S sold 83,562 shares, cutting its stake by 27.7% to 218,180 shares valued at $14.48 million (about 0.06% of DexCom).
• DexCom beat Q1 estimates with non‑GAAP EPS $0.56 vs. $0.47 and revenue $1.19B (up 15%), but the company merely reaffirmed FY26 guidance (~$5.2–$5.3B), prompting mixed analyst reactions and an after‑hours pullback; consensus rating is a "Moderate Buy" with a $83.73 price target.
• Institutional ownership is very high (97.75%), while insiders own 0.32% and an EVP sold 1,700 shares under a Rule 10b5‑1 plan.

Danske Bank A S reduced its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 27.7% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 218,180 shares of the medical device company's stock after selling 83,562 shares during the period. Danske Bank A S owned about 0.06% of DexCom worth $14,481,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of DXCM. Brighton Jones LLC grew its position in shares of DexCom by 257.7% during the 4th quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company's stock valued at $1,290,000 after acquiring an additional 11,946 shares during the period. Integrated Wealth Concepts LLC lifted its stake in shares of DexCom by 6.3% during the 1st quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company's stock valued at $227,000 after buying an additional 196 shares in the last quarter. Empowered Funds LLC lifted its stake in shares of DexCom by 5.4% during the 1st quarter. Empowered Funds LLC now owns 8,446 shares of the medical device company's stock valued at $577,000 after buying an additional 436 shares in the last quarter. Focus Partners Wealth lifted its stake in shares of DexCom by 13.2% during the 1st quarter. Focus Partners Wealth now owns 7,218 shares of the medical device company's stock valued at $493,000 after buying an additional 841 shares in the last quarter. Finally, NewEdge Advisors LLC lifted its stake in shares of DexCom by 1.4% during the 2nd quarter. NewEdge Advisors LLC now owns 19,253 shares of the medical device company's stock valued at $1,681,000 after buying an additional 258 shares in the last quarter. 97.75% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on DXCM shares. Barclays set a $67.00 price target on shares of DexCom and gave the company an "underweight" rating in a research note on Friday. Truist Financial restated a "buy" rating and set a $80.00 price target (down from $82.00) on shares of DexCom in a research note on Tuesday, February 17th. Canaccord Genuity Group set a $100.00 price target on shares of DexCom and gave the company a "buy" rating in a research note on Friday. TD Cowen dropped their price target on shares of DexCom from $84.00 to $75.00 and set a "buy" rating on the stock in a research note on Friday. Finally, BTIG Research restated a "buy" rating and set a $85.00 price target on shares of DexCom in a research note on Monday, March 9th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $83.73.

DexCom Price Performance

Shares of NASDAQ:DXCM opened at $61.35 on Monday. The firm has a fifty day moving average price of $65.87 and a two-hundred day moving average price of $66.41. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.95 and a quick ratio of 1.64. DexCom, Inc. has a one year low of $54.11 and a one year high of $89.98. The company has a market cap of $23.67 billion, a price-to-earnings ratio of 26.22, a PEG ratio of 1.18 and a beta of 1.40.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, beating the consensus estimate of $0.47 by $0.09. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The firm had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.17 billion. During the same period last year, the firm earned $0.32 EPS. The business's quarterly revenue was up 15.0% compared to the same quarter last year. Analysts anticipate that DexCom, Inc. will post 2.52 EPS for the current fiscal year.

Trending Headlines about DexCom

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Q1 beat on both EPS and revenue; non‑GAAP EPS of $0.56 topped estimates and revenue rose 15% to $1.19B with margins improving — a clear near‑term earnings beat that supports upside. DexCom Stock Up on Q1 Earnings & Revenues Beat, Margins Rise
• Positive Sentiment: Company reported record new patient starts globally and cites product momentum plus coverage expansion as drivers — supports sustained top‑line growth and market penetration for its CGM franchise. DXCM Q1 deep dive: US growth moderates as product momentum and coverage expansion drive strategy
• Positive Sentiment: Medicare National Coverage Determination (NCD) remains the biggest catalyst for 2026 per RBC — a favorable NCD could materially expand U.S. addressable market and is being watched by investors. DexCom Medicare Coverage NCD Remains Biggest 2026 Catalyst, RBC Says
• Neutral Sentiment: Management reaffirmed FY26 revenue guidance (~$5.2–$5.3B) rather than raising it; that keeps the outlook intact but removes an upside surprise for the full year amid geopolitical caution. Dexcom reaffirms full-year forecast after topping quarterly estimates
• Negative Sentiment: Some brokerages trimmed price targets (TD Cowen cut to $75; BTIG lowered its PT to $80) even as they keep Buy ratings — reduces near‑term analyst upside and may cap gains. Benzinga
• Negative Sentiment: Shares saw an after‑hours pullback in some sessions despite the beat as investors parsed the lack of an upgraded FY revenue outlook and geopolitical risk; watch volume and guidance commentary in the call transcript/slides. Dexcom falls over 5% despite better-than-expected Q1 print, as revenue guidance disappoints

Insiders Place Their Bets

In other DexCom news, EVP Michael Jon Brown sold 1,700 shares of the company's stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $63.04, for a total value of $107,168.00. Following the transaction, the executive vice president directly owned 111,204 shares in the company, valued at $7,010,300.16. This represents a 1.51% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.32% of the stock is owned by corporate insiders.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company's offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.